Rafael Holdings, Inc. Class B (RFL)

Over the past six months, Rafael Holdings' stock price has experienced a decline. As of April 10, 2026, the share price was $1.26, representing a 25.88% decrease from April 11, 2025. Key events impacting the stock price include earnings reports, the passing of its Lead Independent Director, insider buying, a decline in short interest, and lobbying disclosure. The Q4 Fiscal 2025 financial results were reported on October 29, 2025, with an EPS of -$0.281 USD. The Q1 Fiscal 2026 financial results were reported on December 11, 2025, with an EPS of -$0.192 USD and revenue of $0.24M. The Q2 Fiscal 2026 financial results were reported on March 16, 2026, with a GAAP EPS of -$0.13 and revenue of $0.21 million. On October 28, 2025, Rafael Holdings announced the passing of its Lead Independent Director, Stephen Greenberg, and the appointment of Alan Grayson to its Board of Directors. In June 2025, the Executive Chairman of RFL bought 12,299,207 shares. As of March 13, 2026, short interest in RFL declined by 27.5% from February 26, 2026, totaling 40,019 shares. In Q1 2026, $24,000 of lobbying by Rafael Holdings, Inc. was disclosed, related to issues such as rare pediatric disease Priority Review Vouchers.

There is no direct information available in the provided search results regarding the demand seasonality for Rafael Holdings, Inc.'s specific products and services. The company's primary focus on clinical-stage pharmaceuticals for rare diseases like Niemann-Pick Disease Type C1 suggests that demand would be driven by patient populations and clinical trial progress rather than typical seasonal consumer patterns.

Rafael Holdings, Inc. is a biotechnology company focused on developing pharmaceuticals and holding interests in clinical and early-stage companies involved in pharmaceuticals and medical devices. The company operates through three segments: Healthcare, Infusion Technology, and Real Estate. Its lead clinical candidate is Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1). The company also has interests in other life science and technology businesses, including LipoMedix Pharmaceuticals Ltd., Cornerstone Pharmaceuticals, Inc., Barer Institute Inc., Rafael Medical Devices, LLC, and Day Three Labs, Inc. The real estate segment comprises a portion of a commercial building in Jerusalem, Israel.

Rafael Holdings, Inc. has operations based in the United States and Israel. Its headquarters are located in Newark, New Jersey, United States. The company's real estate assets include properties in Jerusalem, Israel.

Specific information detailing Rafael Holdings, Inc.'s brand reputation or events that have explicitly affected it in the past year is not readily available in the provided search results. The information primarily focuses on financial performance, clinical trials, and corporate governance.

Ownership of Rafael Holdings, Inc. is a mix of institutional, retail, and individual investors, with a significant concentration among insiders. Howard S. Jonas is the largest individual shareholder, owning 29.02% of all shares and 50.4% of the voting power. Major institutional owners and shareholders include Vanguard Group Inc., Geode Capital Management, Llc, Ieq Capital, Llc, BlackRock, Inc., Dimensional Fund Advisors Lp, Founders Fund V Management, LLC, Wells Fargo & Company/mn, Northern Trust Corp, Jane Street Group, Llc and State Street Corp. As of April 10, 2026, institutional investors hold a total of 3,944,032 shares, representing approximately 11.30% of Rafael's stock.